ABOUT

Unlocking the therapeutic potential of mimicry

What if we could engineer therapeutics to trigger the ideal biological response by taking inspiration from mimicry in nature?

Mimicry is one of nature’s oldest tricks in which organisms gain adaptive advantages by imitating others.

We adapted this idea to drug discovery. MIMIC™, our computationally driven bioplatform that couples machine learning with molecular mimicry, engineers therapeutics to trigger a desired biological response.

Our MIMIC platform opens the possibility to develop engineered medicines with specific features to access a range of targets, including those that were previously intractable.

Founded by Flagship Pioneering in 2021, Metaphore aims to unlock breakthroughs that outperform today’s drugs for maximum patient impact.

Leadership

Daniel Acker, PhD

Co-Founder and CIO, Metaphore

Principal, Flagship Pioneering

Lovisa Afzelius, PhD, MBA

Co-Founder and Founding CEO, Metaphore

Origination Partner, Flagship Pioneering

Chaz Hinzman, PhD

Head of Strategy and Operations, Metaphore

Senior Associate, Flagship Pioneering

Marcin Paduch, PhD

Head of Platform, Metaphore

Strategic Oversight Board

Noubar Afeyan, PhD

Co-Founder and Chairman of the Strategic Oversight Board, Metaphore

Founder and CEO, Flagship Pioneering

Lovisa Afzelius, PhD, MBA

Co-Founder and Founding CEO, Metaphore

Origination Partner, Flagship Pioneering

Advisors

Arup Chakraborty, PhD

Scientific Advisor and Academic Partner, Flagship Pioneering

Institute Professor at MIT

Founding Steering Committee Member, Ragon Institute

Daniel Lingwood, PhD

Associate Professor of Medicine, Harvard Medical School

Core Member, Ragon Institute

Ulrich von Andrian, MD

Edward Mallinckrodt Jr. Professor of Immunopathology, Microbiology and Immunobiology, Harvard Medical School

Senior Investigator, von Adrian Lab, Boston Children’s Hospital

Timothy Whitehead, PhD

Associate Professor of Chemical and Biological Engineering, University of Colorado Boulder